tbuckley/cabot-search huggingface dataset:
The number of lymph nodes with metastatic disease portends for a poorer prognosis in women with stage IIIC-IV endometrioid uterine cancer
Authors: J. K. Chan, M. K. Cheung, K. Osann, A. Husain, N. N. Teng, J. S. Berek, D. S. Kapp
Journal: Journal of Clinical Oncology (2006)

5039 Background: To determine the prognosis of women with IIIC-IV endometrioid uterine cancer based on the number lymph nodes with metastatic disease Methods: Demographic and clinico-pathologic information were obtained from the Surveillance, Epidemiology and End Results Program from 1988–2001 and analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Results: Of the 1,222 women diagnosed with stage IIIC-IV endometrioid uterine cancer with nodal disease, the median age was 64 (range: 28–93). All patients underwent surgical staging including a lymph node assessment and were found to have nodal metastases. 639 (52.3%) had stage IIIC, 24 (2.0%) IVA, and 559 (45.7%) IVB disease. The study cohort was divided in three subgroups based on the number of positive nodal metastases: 1, 2–5, and &gt;5. The 5-year overall disease-specific survivals of women with 1, 2–5, and &gt;5 positive nodes were 68.1%, 55.1% and 46.4%, respectively (p &lt; 0.0001). The increasing number of positive nodes was associated with a worsening survival in stage IIIC (77.1%, 60.9%, 69.1%; p = 0.003) and stage IV (50.9%, 49.8%, 38.9%; p = 0.09) diseases. It appears that the extent of benign nodal resection attenuates the increase in the mortality associated with a higher number of positive nodes (see table ). Women with higher number of positive nodes received significantly less adjuvant radiotherapy at 76.8%, 59.5%, and 56.7% respectively. On multivariate analysis, age, stage, grade, number of positive lymph nodes and extent of lymph node resection were significant independent prognostic factors for survival. However, adjuvant radiation was not an important independent prognostic factor in multivariate analysis. Conclusion: Women with node positive endometrioid uterine cancers have a decreased survival associated with increasing number of positive nodes. Our data suggests that the extent of lymph node resection improves the survival of patients with node-positive uterine cancer. [Table: see text] No significant financial relationships to disclose.
Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI).
Authors: Wei Chong Tan, Amit Jain, Sylvaine Barbier, Quan Sing Ng, Ravindran Kanesvaran, Mei-Kim Ang, Angela Takano, Kiat Hon Lim, Wu Meng Tan, Chee Keong Toh, Bibhas Chakraborty, Wan-Teck Lim, Eng Huat Tan, Daniel Shao-Weng Tan
Journal: Journal of Clinical Oncology (2014)

e19101 Background: The relationship between RECIST tumour measurements and clinical outcomes in EGFR mutant NSCLC is not well established. We sought to identify tumour response parameters that correlated with survival in EGFR M+ TKI-treated NSCLC. Methods: CT scans of 115 patients with EGFR-sensitising mutation positive NSCLC treated with first-line EGFR TKI were evaluated retrospectively from start of treatment using RECIST 1.1. Best response (BR), initial response (IR) within 3 mths, time to partial response (PRT), time to best response (BRT) and response heterogeneity were correlated (Spearman’s rho) with progression-free survival (PFS) and overall survival (OS). Results: Baseline demographics: M:F (84:31), median age 62 (33-83), exon 19 (n=65), L858R (n=41), others (n=9). Median PFS was 10.5 mths, response rate 61.9%, and median time to PR/CR 4.4 mths. 93.0% have RECIST measurable lesions. 84.7% with disease progression (PD) had growing target/new lesions. BR and BRT (median 5.7 mths) significantly correlated with PFS (p<.005) and OS (p<.005). At time of BR, SD cases compared to PR did not show poorer PFS (p=.147). Stratifying SD into cases with tumour shrinkage (SD1) and growth (SD2) showed significant difference between PR and SD2 groups in PFS (p=.016) and OS (p=.007). IR significantly correlated with OS (p=.001) not PFS (p=.125). PRT (median 4.4 mths) significantly correlated with PFS (p=.042) not OS (p=.209). A subgroup of patients with initial SD recorded superior PFS when compared to those with PR. 7.2% (n=7) of patients exhibited response heterogeneity, which did not correlate with poorer survival (p=.179). Benefit in continuing TKI past PD (median 16.6 [3.7-14.2] mths) was shown (HR 0.22, p<.001). Conclusions: In this retrospective analysis, BR and BRT correlated with PFS and OS, and may represent potential surrogate endpoints. IR (within 3 mths) did not correlate with PFS, suggesting likelihood of acquiring resistance is independent of an EGFR M+ tumour’s susceptibility to TKI. Patients with SD at BR are heterogeneous and further stratification will facilitate selection for more efficacious therapies (e.g., combination strategies).
Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience
Authors: Ivan Salgado-Ceballos, Jazmín Ríos, Delia Pérez-Montiel, Lenny Gallardo, Salim Barquet-Muñoz, Rosa Salcedo-Hernández, Carlos Pérez-Plasencia, Luis Alonso Herrera, David Francisco Cantú de León
Journal: International Journal of Surgery (2017)
SEX DIFFERENCES IN THE USE OF INFERIOR VENA CAVA FILTERS IN PATIENTS WITH PROXIMAL LOWER EXTREMITY DEEP VEIN THROMBOSIS IN THE UNITED STATES
Authors: Vladimir Lakhter, Chad Zack, Satyajit Reddy, Saurav Chatterjee, Vikas Aggarwal, Deborah Crabbe, Riyaz Bashir
Journal: Journal of the American College of Cardiology (2017)
PROTEOMICS DISCOVERY OF BIOMARKERS FOR ATRIAL FIBRILLATION IN PATIENTS WITH CARDIOVASCULAR DISEASE
Authors: Aspasia Tzani, Ilias P. Doulamis, Asier Antoranz, George Samanidis, Vicky Pliaka, Anastasios Gkogkos, Panagiotis Konstantopoulos, Theodore Sakellaropoulos, Leonidas Alexopoulos, Konstantinos G. Perreas, Despina N. Perrea
Journal: Journal of the American College of Cardiology (2017)
Infective Endocarditis Hospitalizations and Antibiotic Prophylaxis Rates Before and After the 2007 American Heart Association Guideline Revision
Authors: Pallav Garg, Dennis T. Ko, Krista M. Bray Jenkyn, Lihua Li, Salimah Z. Shariff
Journal: Circulation (2019)

Background: In 2007, the American Heart Association recommended antibiotic prophylaxis for the prevention of infective endocarditis (IE) for only the highest-risk patients. Whether this change affected the use of antibiotic prophylaxis and the incidence of IE is unclear. Methods: IE-related hospitalizations were identified from 2002 to 2014 among all adults and those at high and moderate risk for IE, stratified by age. Prescriptions for antibiotic prophylaxis were obtained from the Ontario Drug Benefit database for adults ≥65 years of age. Outcomes were antibiotic prophylaxis prescription rates and incidence of IE-related hospitalization. Trends in patient and pathogen characteristics were analyzed. Time series analyses were performed with segmented regression and change-point analyses. Results: Prescriptions for antibiotic prophylaxis decreased substantially in the moderate-risk cohort after the guideline revision (mean quarterly prescriptions, 30 680 versus 17 954 [level change, −6,481; P =0.0004] per 1 million population) with a minimal, yet significant, decrease followed by a slow increase in the high-risk group. There were 7551 IE-related hospitalizations among 6884 adults ≥18 years of age. Among adults ≥65 years of age, the mean IE rate increased from 872 to 1385 and 229 to 283 per 1 million population at risk per quarter in the high- and moderate-risk groups, respectively. Change-point analyses indicated that this increase occurred in the second half of 2010 in adults ≥65 years of age, 3 years after the American Heart Association guideline revision. Staphylococcus aureus and streptococcal species accounted for 30.3% and 26.4% of all IE, with a decrease in streptococcal infections over time. Conclusions: Antibiotic prophylaxis decreased significantly in the moderate-risk group with minimal change in the high-risk group after the American Heart Association guideline revision in 2007. However, IE-related hospitalizations increased among both high- and moderate-risk patients 3 years after the revision. Our study provides support for the cessation of antibiotic prophylaxis in the moderate-risk population.
PREVALENCE, PREDICTORS AND PROGNOSTIC IMPLICATIONS OF RESIDUAL IMPAIRMENT OF FUNCTIONAL CAPACITY AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION
Authors: Mohammad Abdelghani, Rafael Cavalcante, Yosuke Miyazaki, Robbert de Winter, Rogerio Sarmento-Leite, José Mangione, Alexandre Abizaid, Pedro Lemos, Patrick Serruys, Fabio de Brito
Journal: Journal of the American College of Cardiology (2017)
DESCRIBING COLLABORATION BETWEEN CARDIOLOGY AND PALLIATIVE CARE: A NATIONAL SURVEY STUDY OF CURRENT PRACTICES, CHALLENGES AND BARRIERS
Authors: Keith M. Swetz, Gisella Mancarella, James Dionne-Odom, Sara E. Wordingham, Colleen McIlvennan, Sarah Goodlin, Elizabeth Blume, Karen Alexander, Abby Cestoni, Mathew Maurer, Paul Hauptman, Marie Bakitas, James Kirkpatrick
Journal: Journal of the American College of Cardiology (2017)
Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant (APR) in high (HEC), moderate (MEC) and high dose chemotherapy (HDC) in multiple day chemotherapy (MDC)
Authors: K. Jordan, I. Kinitz, T. Behlendorf, C. Sippel, W. Voigt, H. H. Wolf, H. J. Schmoll
Journal: Journal of Clinical Oncology (2007)

19545 Background: 5-HT 3 receptor antagonists (RA) plus dexamethasone (DEX) has been shown to induce 55–57% complete responses from emesis during the 4–5 days of cisplatin chemotherapy. The role of aprepitant in MDC remains to be defined. The antiemetic triple combination of a NK-1-RA, 5-HT 3 -RA and dexamethasone has not been formally investigated in more than one day chemotherapy. Methods: In this retrospective study, pts. with MDC received APR 125 mg d1, 80 mg consecutive days, granisetron (GRAN) 2 mg daily and DEX 8 mg daily for prevention of acute CINV and APR 80 mg and DEX 8 mg for 2 days for delayed CINV. Endpoints were complete response (CR, no vomiting &amp; no use of rescue therapy) in the acute, delayed and overall phase. Results: Of 103 pts. (f/m 21/82 pts.; median age 40.6y) with various types of cancers 41 pts. (39.8%) received HEC, 44 (42.8%) MEC, and 18 pts. (17.4%) HDC. Median duration of CTX was 3.42 days (HEC 3.9 d). The most frequent regimens were ICE (35%), PEB (14.6%), I3VA (10.7%), MAID (4.9%) and IEV (5.9%). Toxicity: Singultus was reported in 6.8% and loss of appetite in 25.5%. Elevation (CTC grade 1–2) of transaminase/AP/bilirubin and creatinine were seen in comparison to pretreatment values in 15.6%/6.8%/21.1% and 7.8% of all pts.. Efficacy: Acute/delayed/overall CR in HEC was 68.3%/70.7%/63.4%, in MEC 77.3%/84.1%/77.3% and in HDC 77.8%/61.6%/55.6%. Risk factor analysis revealed that pretreatment anxiety increased the risk of vomiting significantly (p= 0.008). Conclusions: Toxicity seems not to be increased by the multiple day treatment of APR (5–7 days) in comparison to the usually used 3-day APR regimen. The CR in the acute and delayed phase in patients receiving HEC was superior to the results reported in the literature with the combination of a 5-HT 3 RA and DEX. The CR in the delayed phase in MEC was better than reported by Warr et al. where pts. receiving only one day of MEC and APR mono in the delayed phase. This might be due to the combination of APR/DEX in the delayed phase in our study. These promising results have to be confirmed in a prospective randomized trial. No significant financial relationships to disclose.
30-DAY UNPLANNED READMISSION RATES, COST, PREDICTORS, AND CAUSES OF HOSPITALIZATION IN ACUTE MYOCARDIAL INFARCTION PATIENTS
Authors: Uvesh Mansuri, Smit Patel, Neel Patel, Rajvee Patel, Ronak Soni, Mohit Pahuja, Dhara Patel, Vinshi Naz Khan
Journal: Journal of the American College of Cardiology (2017)
Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC)
Authors: Karl Smith, None Byrne, Jose Maria Castaño, Maria Dolores Chirlaque, Hans Lilja, Antonio Agudo, Eva Ardanaz, Miguel Rodríguez-Barranco, Heiner Boeing, Rudolf Kaaks, Kay-Tee Khaw, Nerea Larrañaga, Carmen Navarro, Anja Olsen, Kim Overvad, Aurora Perez-Cornago, Sabine Rohrmann, Maria José Sánchez, Anne Tjønneland, Konstantinos K. Tsilidis, Mattias Johansson, Elio Riboli, Timothy J. Key, Ruth C. Travis
Journal: Journal of Clinical Oncology (2017)

Purpose Vasectomy is a commonly used form of male sterilization, and some studies have suggested that it may be associated with an increased risk of prostate cancer, including more aggressive forms of the disease. We investigated the prospective association of vasectomy with prostate cancer in a large European cohort, with a focus on high-grade and advanced-stage tumors, and death due to prostate cancer. Patients and Methods A total of 84,753 men from the European Prospective Investigation into Cancer and Nutrition (EPIC), aged 35 to 79 years, provided information on vasectomy status (15% with vasectomy) at recruitment and were followed for incidence of prostate cancer and death. We estimated the association of vasectomy with prostate cancer risk overall, by tumor subtype, and for death due to prostate cancer, using multivariable-adjusted Cox proportional hazards models. Results During an average follow-up of 15.4 years, 4,377 men were diagnosed with prostate cancer, including 641 who had undergone a vasectomy. Vasectomy was not associated with prostate cancer risk (hazard ratio [HR], 1.05; 95% CI, 0.96 to 1.15), and no evidence for heterogeneity in the association was observed by stage of disease or years since vasectomy. There was some evidence of heterogeneity by tumor grade ( P = .02), with an increased risk for low-intermediate grade (HR, 1.14; 95% CI, 1.01 to 1.29) but not high-grade prostate cancer (HR, 0.83; 95% CI, 0.64 to 1.07). Vasectomy was not associated with death due to prostate cancer (HR, 0.88; 95% CI, 0.68 to 1.12). Conclusion These findings from a large European prospective study show no elevated risk for overall, high-grade or advanced-stage prostate cancer, or death due to prostate cancer in men who have undergone a vasectomy compared with men who have not.
PREHOSPITAL ADMINISTRATION OF HEPARIN REDUCES THE RISK OF VESSEL OCCLUSION IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION: SECONDARY ANALYSIS OF THE TASTE TRIAL
Authors: Sofia Karlsson, Moman A. Mohammad, Pontus Andell, Bo Lagerqvist, Stefan James, Goran Olivecrona, Ole Frobert, David Erlinge
Journal: Journal of the American College of Cardiology (2017)
Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Felix Rosenow, Gerda Silling, Berkemeier Almut, Carsten Mueller-Tidow, Steffen Koschmieder, Guido Bisping, Utz Krug, Thomas Buechner, Wolfgang E Berdel, Joachim Kienast, Matthias Stelljes
Journal: Blood (2009)
Phase II study of bevacizumab (Bv) in combination with paclitaxel-carboplatin (PC) as first-line chemotherapy for nonsquamous (SQ) non-small cell lung cancer (NSCLC) with malignant pleural effusion (MPE).
Authors: Motohiro Tamiya, Tomonori Hirashima, Akihiro Tamiya, Norio Okamoto, Hidekazu Suzuki, Tadahiro Yamadori, Naoko Morishita, Takayuki Shiroyama, Tomoyuki Otsuka, Kanako Kitai, Tomomi Yasue, Kazuhiro Asami, Shojiro Minomo, Syoko Sonobe, Keiko Nakao, Tomoya Kawaguchi, Shinji Atagi, Ichiro Kawase
Journal: Journal of Clinical Oncology (2013)

e19021 Background: Vascular endothelial growth factor (VEGF) plays an important role in NSCLC with MPE, but the evidence regarding the efficacy of Bv with PC for treatment of NSCLC with MPE is lacking. Therefore, we prospectively evaluated the efficacy and safety of Bv and PC in non-SQ NSCLC pts. Methods: Chemotherapy-naive non-SQ NSCLC pts with MPE were eligible to participate. Pleurodesis before chemotherapy was not allowed. The treated pts received PC without Bv in the first cycle to prevent Bv-induced delayed wound healing after chest drainage. Subsequently, they received 2–6 cycles of PC with Bv. Patients who completed more than 3 cycles of PC and Bv without disease progression or severe toxicities continued to receive Bv alone as a maintenance therapy. The primary endpoint was overall response, although an increase in MPE was allowed in the first cycle. The plasma and MPE VEGF levels were measured at baseline and the plasma VEGF levels after 3 cycles of chemotherapy. Results: Between September 1, 2010 and June 30, 2012, 23 pts were enrolled. The overall response rate was 60.8%, and the disease control rate was 87.0%. No pts showed complete response, 14 showed partial responses, 6 showed stable disease, 2 showed disease progression, and 1 died in the first cycle. Sixteen pts received maintenance therapy, following a median of 3 cycles. The median progression-free survival period for all pts was 200 days (95% CI, 156–263 days), whereas the median overall survival was 328 days (95% CI, 206–415 days). All pts experienced high levels of hematological toxicities, with most pts experiencing neutropathic toxicities above grade 3. However, none of the pts experienced severe bleeding events. The median baseline MPE VEGF level was 1798.6 (range, 223.4–35,633.4) pg/mL. The plasma VEGF levels showed a significant decrease after 3 chemotherapy cycles (baseline, 513.6 ± 326.4 pg/mL; post-chemotherapy: 25.1 ± 14.1 pg/mL; p &lt; 0.01), regardless of the degree of efficacy. Conclusions: The combination of PC with Bv was confirmed to be effective and reasonably well-tolerated in chemotherapy-naïve non-SQ NSCLC pts with MPE. Clinical trial information: UMIN000005284.
Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.
Authors: Helena Alexandra Yu, Camelia S. Sima, Alexander Edward Dela Cruz Drilon, Anna M. Varghese, Maria Catherine Pietanza, Christopher G. Azzoli, Naiyer A. Rizvi, Lee M. Krug, Mark G. Kris, Vincent A. Miller, Gregory J. Riely
Journal: Journal of Clinical Oncology (2012)

7527 Background: The utility of EGFR directed therapy for the treatment of EGFR mutant lung cancer is limited by the development of acquired resistance (AR) to EGFR tyrosine kinase inhibitor (TKI) therapy, which occurs after a median of 16 months (mos). There are no approved targeted therapies after disease progression on EGFR TKI therapy. Local therapy for oligometastatic disease is used with regularity in other solid tumors, and can lead to long term survival in selected individuals. EGFR mutant lung cancers with AR to TKI therapy can follow an indolent course that is amenable to local therapy to treat progression of disease when used in conjunction with continued EGFR inhibition. Outcomes following local therapy in this setting have not been assessed. Methods: Patients (pts) with AR to EGFR TKI’s who received local therapy excluding treatment of CNS metastases or local therapy prior to AR were identified in an IRB-approved prospective registry of 184 pts with AR enrolled from August 2004- November 2011. We collected treatments as well as progression free survival (PFS) and overall survival (OS) after local therapy. Results: 18 pts received local therapy. Treatments included surgical resection and radiation to lung, lymph nodes, adrenal gland or bone. Median age was 57, 56% were women, and 61% were never smokers. 14 had EGFR Exon 19 deletions, and 4 L858R. The median time to development of AR on TKI was 19 mo (range 5-33). Known mechanisms of AR included T790M (11 pts), MET amplification (1 pt) and small cell transformation (1 pt). The median PFS after local therapy was 10 mo (95% CI: 4-NA), median time from local therapy until change in systemic therapy was 22 mo (95%CI: 6 - 30), and median OS from local therapy was 41 mo (95% CI: 26-NA). Local therapy was tolerated well, with 85% of pts restarting TKI therapy within one month of completing local therapy. Conclusions: Local therapy is well tolerated and in combination with continued EGFR TKI therapy prolongs time until change in systemic therapy is required and may lead to outcomes that are superior to currently available treatment options in selected individuals.
<i>LKB1</i> mutations in mucinous bronchioloalveolar carcinoma occurring in Peutz-Jeghers syndrome patients
Authors: A. Osoegawa, Y. Takeda, T. Kometani, K. Ondo, S. Fukuyama, F. Hirai, K. Nosaki, T. Seto, S. Oda, Y. Ichinose
Journal: Journal of Clinical Oncology (2009)

11047 Background: Mutations in the gene encoding Liver Kinase B1, LKB1, are common in patients with Peutz-Jeghers syndrome (PJS), which is characterized by mucocutaneous pigmentation, intestinal polyps and a high incidence of cancers at variable sites (colorectal, gynecological, breast, pancreas, and lung). Although tumors occurring in PJS patients are known to contain mucin-rich conmponents, mucinous bronchioloalveolar carcinomas (mBACs) arising from the PJS background have only rarely been reported. Here we report two mBAC patients with PJS. We further explored the LKB1 gene in these two patients and, in addition, eight sporadic mBAC patients. Methods: Frozen tissue specimens were collected from ten mBAC patients who underwent surgery in our department from 2002 to 2008, and high molecular weight genomic DNA was extracted from them and stocked in the bio-bank. Written informed consent was obtained from each patient, and ethical approval was obtained from the IRB. The nucleotide sequence of LKB1 (EX01–09) was determined by genomic PCR-direct sequencing. Loss of heterozygosity (LOH) was analyzed by high resolution fluorescent microsatellite analysis (HRFMA) using two microsatellite markers that encompass the LKB1 locus, D19S886 and D19S565. Results: Among 11 tumors derived from the 10 patients, 9 distinct LKB1 mutations were found in 7 tumors (4 G:C to A:T transitions; 3 G:C to C:G transversions; 2 single nucleotide insetion/deletion). All of three tumors obtained from the two PJS patients harbored a same sequence alteration. Although LOH was not observed in these tumors, independent sequence alterations were found in two of the three tumors, which may suggest biallelic inactivation of LKB1 in tumors occurred in the PJS patients. Conclusions: The relatively high frequency of LKB1 mutation in mBAC patients may suggest its implication in lung carcinogenesis, at least in mBAC, and its potential as a therapeutic target. [Table: see text] No significant financial relationships to disclose.
USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA
Authors: Shaun G. Goodman, Gregory Schwartz, Deepak L. Bhatt, Vera Bittner, Rafael Diaz, Corinne Hanotin, Robert Harrington, Johan Jukema, Angele Moryusef, Robert Pordy, Matthew Roe, William J. Sasiela, Michael Szarek, Jean-Francois Tamby, Harvey White, Andreas Zeiher
Journal: Journal of the American College of Cardiology (2017)